• KDventures portfolio company Umecrine Cognition will attend the MJFF Parkinson’s Disease Therapeutics Conference in New York on Oct. 14-15, 2026.
• Umecrine Cognition will also join an invitation-only pre-conference showcase for MJFF therapeutics funding portfolio companies around PDTC 2026.
• Presentation to feature new preclinical translational data on golexanolone in an α-synuclein-driven Parkinson’s model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on October 07, 2026, and is solely responsible for the information contained therein.